Position in NGEN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,060,000
New position
Shares Held
1,000,000
first reported quarter
Ownership
0.930%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#4
of 62 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ghisallo Capital Management LLC holds $223,098,750 across 50 Biotechnology names. NGEN ranks #28 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MLYS |
Mineralys Therapeutics, Inc.
|
1,125,000 | $30,352,500 | |
| 2 | LEGN |
Legend Biotech Corp
|
1,000,000 | $28,880,000 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
1,200,000 | $20,304,000 | |
| 4 | CYTK |
Cytokinetics Inc
|
170,000 | $14,482,300 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
50,000 | $9,364,000 | |
| 6 | ABVX |
Abivax S.A.
|
48,000 | $6,396,480 | |
| 7 | ALLO |
Allogene Therapeutics, Inc.
|
3,000,000 | $6,240,000 | |
| 8 | KOD |
Kodiak Sciences Inc.
|
150,000 | $5,844,000 |
All Filings in NGEN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,060,000 | 1,000,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||